Tumor Mutation Burden and Mutation Influence Long-term Survival in Surgically Resected Small Cell Lung Cancer

Overview

Journal Transl Lung Cancer Res

Date 2024 Jul 8

PMID 38973948

Authors

Xinyu Qian

Lin Zhu

Na Han

Jing Qin

Affiliations

Soon will be listed here.

Abstract

Background: Small cell lung cancer (SCLC) is highly malignant and has a higher risk of recurrence even in patients who undergo early surgery. However, a subgroup of patients survived for many years. So far, the factors that determine the long-term survivorship remain largely unknown. To determine the genetic characteristics of long-term survival (LTS) after surgery in SCLC, we performed comprehensive comparative genomic profiling and tumor mutation burden (TMB) analysis of resected tumor tissues from patients with LTS and short-term survival (STS) after surgery.

Methods: The present study screened 11 patients from 52 patients with SCLC who underwent surgery at Zhejiang Cancer Hospital from April 2008 to December 2017. A total of six LTS patients (≥4 years) with stage IIB or IIIA SCLC and five STS patients (<2 years) with stage IA or IB SCLC were included in the study. The STS patients were used as a control. All the patients underwent resection without neoadjuvant therapy. We assessed the genomic profiles of the resected tumor tissues and calculated the TMB using next-generation sequencing. We then analyzed and compared the molecular characteristics between the LTS and STS groups.

Results: Our data indicated that tumor tissues from patients with LTS harbor a high TMB. The median TMB for LTS patients was high (approximately 16.4 mutations/Mb), while that for STS patients was low (approximately 8.5 mutations/Mb). The median TMB of patients with LTS and STS showed a trend of significant difference (P=0.08). Gene alterations characterized the survival differences between the two groups. The mutation was only found in the LTS group, and the P value determined by Fisher's exact test was 0.06.

Conclusions: A high non-synonymous TMB and the mutation could potentially influence LTS after SCLC resection. This study provides valuable information about the molecular differences between LTS and STS patients. Studies with larger sample sizes need to be conducted to confirm our findings in the future.

References

Zhu H, Zhou Z, Xue Q, Zhang X, He J, Wang L . Treatment modality selection and prognosis of early stage small cell lung cancer: retrospective analysis from a single cancer institute. Eur J Cancer Care (Engl). 2013; 22(6):789-96. DOI: 10.1111/ecc.12082. View

Zhang D, Lu B, Liang B, Li B, Wang Z, Gu M . Interpretable deep learning survival predictive tool for small cell lung cancer. Front Oncol. 2023; 13:1162181. PMC: 10196231. DOI: 10.3389/fonc.2023.1162181. View

Cai W, Zhou D, Wu W, Tan W, Wang J, Zhou C . MHC class II restricted neoantigen peptides predicted by clonal mutation analysis in lung adenocarcinoma patients: implications on prognostic immunological biomarker and vaccine design. BMC Genomics. 2018; 19(1):582. PMC: 6090856. DOI: 10.1186/s12864-018-4958-5. View

Megyesfalvi Z, Barany N, Lantos A, Valko Z, Pipek O, Lang C . Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small-cell lung cancer: an international multicenter study. J Pathol. 2022; 257(5):674-686. PMC: 9541929. DOI: 10.1002/path.5922. View

Leuzzi G, Lococo F, Alessandrini G, Sperduti I, Spaggiari L, Venuta F . Prognostic Impact of Node-Spreading Pattern in Surgically Treated Small-Cell Lung Cancer: A Multicentric Analysis. Lung. 2016; 195(1):107-114. DOI: 10.1007/s00408-016-9954-4. View

Megyesfalvi Z, Gay C, Popper H, Pirker R, Ostoros G, Heeke S . Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions. CA Cancer J Clin. 2023; 73(6):620-652. DOI: 10.3322/caac.21785. View

Cheng Y, Fan Y, Zhao Y, Huang D, Li X, Zhang P . Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial. J Thorac Oncol. 2024; 19(7):1073-1085. DOI: 10.1016/j.jtho.2024.03.008. View

Zhou H, Hu Y, Luo R, Zhao Y, Pan H, Ji L . Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer. Nat Commun. 2021; 12(1):5431. PMC: 8440529. DOI: 10.1038/s41467-021-25787-x. View

Cai R, Zhu H, Liu Y, Sha H, Peng W, Yin R . To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations. J Cancer Res Clin Oncol. 2023; 149(12):10027-10040. PMC: 10423141. DOI: 10.1007/s00432-023-04919-4. View

10.

Zhu L, Qin J . Predictive biomarkers for immunotherapy response in extensive-stage SCLC. J Cancer Res Clin Oncol. 2024; 150(1):22. PMC: 10799815. DOI: 10.1007/s00432-023-05544-x. View

11.

Jiang Z, Zhu M, Zhang L, Cui H, Jiang R, Yang Y . Antitumor immunity and prognosis value elicited by FAT3 and LRP1B co-mutation in endometrial cancer. Gynecol Oncol. 2024; 187:1-11. DOI: 10.1016/j.ygyno.2024.04.023. View

12.

Liu S, Mok T, Nabet B, Mansfield A, de Boer R, Losonczy G . Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide. Lung Cancer. 2023; 186:107418. DOI: 10.1016/j.lungcan.2023.107418. View

13.

Varlotto J, Recht A, Flickinger J, Medford-Davis L, Dyer A, DeCamp M . Lobectomy leads to optimal survival in early-stage small cell lung cancer: a retrospective analysis. J Thorac Cardiovasc Surg. 2011; 142(3):538-46. DOI: 10.1016/j.jtcvs.2010.11.062. View

14.

Paz-Ares L, Garassino M, Chen Y, Reinmuth N, Hotta K, Poltoratskiy A . Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational Burden. Clin Cancer Res. 2023; 30(4):824-835. PMC: 10870117. DOI: 10.1158/1078-0432.CCR-23-1689. View

15.

Gay C, Stewart C, Park E, Diao L, Groves S, Heeke S . Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021; 39(3):346-360.e7. PMC: 8143037. DOI: 10.1016/j.ccell.2020.12.014. View

16.

Bray F, Laversanne M, Sung H, Ferlay J, Siegel R, Soerjomataram I . Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024; 74(3):229-263. DOI: 10.3322/caac.21834. View

17.

Valero C, Lee M, Hoen D, Zehir A, Berger M, Seshan V . Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase. JAMA Oncol. 2021; 7(5):739-743. PMC: 7893543. DOI: 10.1001/jamaoncol.2020.7684. View

18.

Cibulskis K, Lawrence M, Carter S, Sivachenko A, Jaffe D, Sougnez C . Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013; 31(3):213-9. PMC: 3833702. DOI: 10.1038/nbt.2514. View

19.

Yuan T, Wang X, Sun S, Cao Z, Feng X, Gao Y . Profiling of 520 Candidate Genes in 50 Surgically Treated Chinese Small Cell Lung Cancer Patients. Front Oncol. 2021; 11:644434. PMC: 8217828. DOI: 10.3389/fonc.2021.644434. View

20.

Liao K, Yang Q, Xu Y, He Y, Wang J, Li Z . Identification of signature of tumor-infiltrating CD8 T lymphocytes in prognosis and immunotherapy of colon cancer by machine learning. Clin Immunol. 2023; 257:109811. DOI: 10.1016/j.clim.2023.109811. View